MDS 2023 | Factors driving the transformation of CHIP to MDS
Jason Cheng, The University of Chicago, Chicago, IL, explains the current gap in knowledge surrounding progression from clonal hematopoiesis of indeterminate potential (CHIP) to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr Cheng notes that some, but not all, patients with CHIP-associated mutations progress quickly and have poor outcomes, and that some patients also show high expression of cytosine methyltransferases. However, Dr Cheng emphasizes that little is understood regarding the impacts of RNA modifications and mutations on disease progression. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
